Loading...

Emily Bergsland, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-514-6520
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Wisconsin, Madison, WI BS 05/1985Biochemistry/Molecular Biology
    University of Minnesota, Minneapolis, MNMD06/1989Medicine
    University of California (UCSF), San FranciscoResidency 06/1992Internal Medicine
    University of California (UCSF), San Francisco06/1993Chief Residency
    University of California (UCSF), San FranciscoFellowship06/1995Medical Oncology
    University of California (UCSF), San Francisco06/1998Molecular Medicine Training Program
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns? J Nucl Med. 2020 Jun 23. Bodei L, Bergsland EK, de Herder WK, Ferone D, Hicks RJ, Hope TA, Kunikowska JA, Pavel M, Reidy-Lagunes DL, Siveke J, Strosberg JR, Dittmer U, Herrmann K. PMID: 32576637.
      View in: PubMed   Mentions:    Fields:    
    2. Reply to S. Boutayeb et al. JCO Oncol Pract. 2020 Jun 23; OP2000394. Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. PMID: 32574129.
      View in: PubMed   Mentions:
    3. Intra-arterial Peptide Receptor Radionuclide Therapy using 90Y DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. J Nucl Med. 2020 Jun 08. Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA. PMID: 32513903.
      View in: PubMed   Mentions:    Fields:    
    4. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas. 2020 May 19. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. PMID: 32433264.
      View in: PubMed   Mentions:    Fields:    
    5. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. JCO Oncol Pract. 2020 Apr 30; OP2000239. Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. PMID: 32352884.
      View in: PubMed   Mentions:
    6. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020 Jul 01; 126(13):3021-3030. Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. PMID: 32320048.
      View in: PubMed   Mentions:    Fields:    
    7. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors. J Surg Oncol. 2020 Apr 14. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. PMID: 32291778.
      View in: PubMed   Mentions:    Fields:    
    8. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2020 Mar 07. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. PMID: 32146619.
      View in: PubMed   Mentions:    Fields:    
    9. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res. 2020 May 01; 26(9):2124-2130. Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J. PMID: 31980466.
      View in: PubMed   Mentions:    Fields:    
    10. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. J Surg Oncol. 2019 Dec 11. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK. PMID: 31828813.
      View in: PubMed   Mentions:    Fields:    
    11. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. PMID: 30058032.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. J Patient Rep Outcomes. 2019 Oct 26; 3(1):64. Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P. PMID: 31655936.
      View in: PubMed   Mentions:
    13. Prognostic impact of a large mesenteric mass >2?cm in ileal neuroendocrine tumors. J Surg Oncol. 2019 Dec; 120(8):1311-1317. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. PMID: 31613999.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors. Pancreas. 2019 08; 48(7):948-952. Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA. PMID: 31268975.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One. 2019; 14(7):e0219469. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. PMID: 31291332.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 06 01; 37(16):1436-1447. Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N. PMID: 30986117.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases. Pancreas. 2019 04; 48(4):496-503. Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K. PMID: 30946246.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist. 2019 08; 24(8):e662-e670. Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. PMID: 30651397.
      View in: PubMed   Mentions:    Fields:    
    19. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Transl Oncol. 2019 Mar; 12(3):550-560. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS. PMID: 30639964.
      View in: PubMed   Mentions:
    20. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist. 2019 08; 24(8):1066-1075. Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. PMID: 30610008.
      View in: PubMed   Mentions:    Fields:    
    21. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist. 2019 08; 24(8):1056-1065. Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. PMID: 30606883.
      View in: PubMed   Mentions:    Fields:    
    22. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018 11 01; 4(11):1597-1604. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E. PMID: 30054622.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 12; 17(12):2702-2709. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. PMID: 30254185.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    24. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. Mod Pathol. 2019 02; 32(2):290-305. Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM. PMID: 30237525.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018 08; 14(8):487-489. Mulvey CK, Bergsland EK. PMID: 30096272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 06; 16(6):693-702. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. PMID: 29891520.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    27. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clin Ther. 2018 06; 40(6):952-962.e2. Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. PMID: 29724499.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    28. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clin Ther. 2017 Nov; 39(11):2158-2168. Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. PMID: 29074312.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    29. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018 01; 59(1):66-74. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. PMID: 29025982.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Fam Cancer. 2017 10; 16(4):537-543. Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. PMID: 28283864.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017 07; 46(6):715-731. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. PMID: 28609357.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    32. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):707-714. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. PMID: 28609356.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    33. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist. 2017 07; 22(7):768-773. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. PMID: 28507205.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    34. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Med Oncol. 2017 May; 34(5):88. Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. PMID: 28393314.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017; 5:22. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. PMID: 28344808.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    36. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas. 2017 03; 46(3):416-426. Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK. PMID: 28187108.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. PMID: 28078110.
      View in: PubMed   Mentions:
    38. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 11; 45(10):1394-1400. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. PMID: 27171514.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    39. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan; 35(1):14-23. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. PMID: 27918724.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    40. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 05; 23(5):411-8. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. PMID: 27080472.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    41. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016 08; 23(8):2548-55. Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. PMID: 27020587.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    42. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):63-82. Mulvey CK, Bergsland EK. PMID: 26614369.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    44. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Phys. 2015 Dec; 2(1):21. Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK. PMID: 26501822.
      View in: PubMed   Mentions:
    45. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. PMID: 25820755.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    46. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 01; 121(19):3481-90. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. PMID: 26177599.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    47. Transcatheter pulmonic valve replacement in carcinoid heart disease. Eur Heart J Cardiovasc Imaging. 2015 Sep; 16(9):1046. Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK. PMID: 26003151.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 2015 Apr 28; 11(4):577-91. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. PMID: 25892230.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    49. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts? J Clin Oncol. 2015 May 10; 33(14):1523-6. Bergsland EK. PMID: 25646187.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Is more not better?: combination therapies in colorectal cancer treatment. Hematol Oncol Clin North Am. 2015 Feb; 29(1):85-116. Bergsland EK. PMID: 25475574.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    51. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015; 92-103. Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. PMID: 25993147.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. PMID: 25583772.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    53. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015 Mar; 4(1):9-17. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK. PMID: 25430999.
      View in: PubMed   Mentions:
    54. Neuroendocrine tumors of unknown primary: is the primary site really not known? JAMA Surg. 2014 Sep; 149(9):889-90. Bergsland EK, Nakakura EK. PMID: 25029597.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. PMID: 25012985.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    56. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014 Jun 16; 25(6):809-821. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM. PMID: 24909985.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    57. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    58. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol. 2014 Apr; 73(4):695-702. Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK. PMID: 24488322.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    59. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    60. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. PMID: 23542178.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    61. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    62. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):1-3. Bergsland EK. PMID: 23391108.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):4-22. Bergsland EK. PMID: 23391109.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    64. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    65. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012 Aug; 41(6):840-4. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. PMID: 22781907.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    66. Systemic therapy for advanced carcinoid tumors: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 01; 10(6):785-93. Paulson AS, Bergsland EK. PMID: 22679120.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    67. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):724-64. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. PMID: 22679117.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    68. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. PMID: 22270257.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    69. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011 Jul; 254(1):97-102. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. PMID: 21494121.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    70. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. PMID: 21263089.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    71. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK. PMID: 20599218.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. PMID: 20231629.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    73. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. PMID: 20048018.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    74. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    75. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 08; 360(2):195-7. Kulke MH, Bergsland EK, Yao JC. PMID: 19129539.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    76. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer. 2009 Mar; 16(1):267-79. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK. PMID: 18987169.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    77. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. PMID: 18815548.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    78. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10; 26(20):3403-10. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. PMID: 18612155.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCTClinical Trials
    79. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. PMID: 18379729.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    80. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 18181045.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    81. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. 2008 Jan; 7(1):44-7. Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. PMID: 18279576.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    82. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct 20; 25(30):4793-9. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. PMID: 17947727.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    83. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007 Aug 15; 99(16):1232-9. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. PMID: 17686822.
      View in: PubMed   Mentions: 221     Fields:    Translation:Humans
    84. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer? Surg Oncol Clin N Am. 2007 Jul; 16(3):639-51, x. Nakakura EK, Venook AP, Bergsland EK. PMID: 17606198.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am. 2007 Jun; 21(3):457-73; viii. Nakakura EK, Bergsland EK. PMID: 17548034.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    86. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. PMID: 17363191.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    87. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 01; 24(22):3555-61. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. PMID: 16877721.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    88. Pancreatoblastoma in an adult: case report and review of the literature. J Gastrointest Surg. 2006 Jun; 10(6):829-36. Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK. PMID: 16769539.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    89. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev. 2006 Jun; 25(2):279-92. Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H. PMID: 16770540.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    90. When does the presence of the target predict response to the targeted agent? J Clin Oncol. 2006 Jan 10; 24(2):213-6. Bergsland EK. PMID: 16365177.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    91. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 16344320.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    92. Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol. 2005 Sep; 6(5):411-21. Whisenant J, Bergsland E. PMID: 16107244.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    93. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. PMID: 15999098.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    94. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 01; 23(16):3706-12. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. PMID: 15867200.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCTClinical Trials
    95. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res. 2005 Mar 01; 11(5):1791-7. Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM. PMID: 15756001.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    96. Update on clinical trials targeting vascular endothelial growth factor in cancer. Am J Health Syst Pharm. 2004 Nov 01; 61(21 Suppl 5):S12-20. Bergsland EK. PMID: 15552622.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    97. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm. 2004 Nov 01; 61(21 Suppl 5):S4-11. Bergsland EK. PMID: 15552621.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    98. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematol Oncol Clin North Am. 2004 Oct; 18(5):1087-119, ix. Allen J, Bergsland EK. PMID: 15474337.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    99. Maximizing the potential of bevacizumab in cancer treatment. Oncologist. 2004; 9 Suppl 1:36-42. Bergsland E, Dickler MN. PMID: 15178814.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    100. Couples therapy at end of life. Psychooncology. 2003 Sep; 12(6):620-7. Mohr DC, Moran PJ, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E, Folkman S. PMID: 12923802.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    101. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003 May; 111(9):1287-95. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. PMID: 12727920.
      View in: PubMed   Mentions: 375     Fields:    Translation:AnimalsCells
    102. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med. 2003 Apr 21; 197(8):1017-28. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D. PMID: 12695493.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    103. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 01; 21(1):60-5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. PMID: 12506171.
      View in: PubMed   Mentions: 356     Fields:    Translation:HumansCTClinical Trials
    104. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):192-6. Ko AH, Bergsland EK, Lee GA. PMID: 12645810.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. Shedding old paradigms: developing viruses to treat cancer. J Clin Oncol. 2002 May 01; 20(9):2220-2. Bergsland EK, Venook AP. PMID: 11980991.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    106. Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol. 2001 Oct; 28(5):521-31. Bergsland EK. PMID: 11685745.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    107. Hepatocellular carcinoma. Curr Opin Oncol. 2000 Jul; 12(4):357-61. Bergsland EK, Venook AP. PMID: 10888422.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    108. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000 Apr; 105(8):1045-7. Hanahan D, Bergers G, Bergsland E. PMID: 10772648.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansAnimalsCells
    109. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion. Invasion Metastasis. 1997; 17(1):42-52. Bullard KM, Banda MJ, Arbeit JM, Bergsland E, Young DM. PMID: 9425323.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    Emily's Networks
    Concepts (400)
    Derived automatically from this person's publications.
    _
    Co-Authors (74)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _